Incanthera

About:

Incanthera Ltd. develops cancer treatment drugs. Its ICT-2588 is a lead compound that is activated within solid tumours by a specific

Website: http://www.incanthera.com

Top Investors: The North West Fund

Description:

Incanthera Ltd. develops cancer treatment drugs. Its ICT-2588 is a lead compound that is activated within solid tumours by a specific matrix metalloprotease enzyme. The company was incorporated in 2010 and is based in Liverpool, United Kingdom.

Total Funding Amount:

3.25M GBP

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Liverpool, Liverpool, United Kingdom

Founded Date:

2010-01-01

Contact Email:

info(AT)incathera.com

Founders:

Laurence Patterson

Number of Employees:

1-10

Last Funding Date:

2024-06-03

IPO Status:

Public

Industries: